The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice.

e12656Background: The biosimilar of trastuzumab (Herticad ®) used in Russian clinical practice since March 2016, but the effectiveness, safety and economic rationality of biosimilar of trastuzumab (BT) in the neoadjuvant chemotherapy in HER2+ breast cancer (BC) have not been previously reported. Methods: In our study included 55 women with HER2+ BC stage II-III treated in National Research Cancer Center since March 2016 to December 2017 (median age- 52; range - 28-80 years). Neoadjuvant chemotherapy was used in all women (sequential combination of anthracyclines and taxanes, AC→T - 59,3%, taxanes plus carboplatin, DC -37%, taxanes only -3,7%) with BT at a standard dose 6 mg/kg (loading first dose 8 mg/kg), every 3 weeks. Primary-operable stages were in 45,5%, locally advance stages - in 54,4%. Grade of tumors was G2 in 83%, G3- in 17%; luminal HER2+ BC was seen in 45,5%, non-luminal HER2+ BC - in 54,5%. After neoadjuvant chemotherapy with BT all women had radical surgery with an assessment of the patholog...